SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Börse Frankfurt
Börse Börse Frankfurt
ISIN US0727303028
EUR
  • BAYER AG NA O.N.
    Börse Börse Hamburg
    ISIN DE000BAY0017 WKN: BAY001
    Symbol BAYN
    EUR
  • BAYER AG
    Börse Xetra Frankfurt
    ISIN XS2199266003 WKN: 879501
    Symbol BAYN
    EUR
  • Bayer
    Börse Börse Frankfurt
    ISIN US0727303028 WKN: 879501
    Symbol BAYA
    EUR
  • BAYER AG NA O.N.
    Börse Börse München
    ISIN XS2199266268
    Symbol BAYN
    EUR
  • Bayer
    Börse Xetra Frankfurt
    Symbol BAYN
    EUR
  • BAYER AG-REG
    Börse Börse Stuttgart
    Symbol BAYN
    EUR
  • BAYER AG-REG
    Börse Quotrix System der Börse Düsseldorf
    Symbol BAYN
    EUR
  • BAYER AG-SPONSORED ADR
    Börse Gettex System der Börse München
    Symbol BAYA
    EUR
  • BAYER AG-REG
    Börse Gettex System der Börse München
    Symbol BAYN
    EUR
  • BAYER AG-REG
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol BAYN
    EUR
  • BAYER AG-REG
    Börse Börse Düsseldorf
    Symbol BAYN
    EUR
  • BAYER AG
    Börse Börse München
    ISIN DE000BAY0017
  • BAYER AG-SPONSORED ADR
    Börse Börse Stuttgart
    Symbol BAYA
    EUR
  • Bayer
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN DE000BAY0017 WKN: BAY001
    Symbol BAYN
    USD
  • Bayer
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN DE000BAY0017 WKN:
    Symbol BAYN.GY
  • Bayer
    Börse Bolsa Mexicana de Valore Mexiko-Stadt
    Symbol BAYN.GY
    MXN
  • ISIN DE000A11QR73
    MXN
  • Symbol BAYN
    EUR
  • ISIN DE000BAY0017 WKN: BAY001
    Symbol BAYN
  • USD
  • USD
  • BAYER AG
    Börse Bolsa de Comercio de Buenos Aires
  • Symbol BAYA
  • EUR
ISIN US0727303028
WKN 879501
Symbol BAYA
Währung EUR
Börse Börse Frankfurt Zeitzone: America/New_York
Marktkapitalisierung 25.008.341.140 (+- 89%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

2.767.000.000 oder 47.249.682.280

Mitarbeiter 100.029 (+- 1%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

100.618 oder 99.439 Mitarbeiter

Anzahl Aktien 982.424.000
KGV 17.5

Zahlte zuletzt am 28.04.2021 eine Dividende von 0,604  . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht

Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 11,5 EUR +0,87% 

Analystenmeinungen

Übersicht

Letzte Communitymeinungen

Ein User hat Bayer abonniert.

Aktionärsstruktur der Bayer

312 News & Informationen zur Bayer Aktie

  • BAYER AG : Buy rating from Kepler Cheuvreux
    marketscreener.com

    BAYER AG : Buy rating from Kepler Cheuvreux

    Christian Faitz from Kepler Cheuvreux retains his positive opinion on the stock with a Buy rating. The target price remains set at EUR 68. | August 17, 2021

  • Bayer takes legal battle over Roundup cancer claims to US Supreme Court
    foxbusiness.com

    Bayer takes legal battle over Roundup cancer claims to US Supreme Court

    Bayer, trying to contain billions of dollars in legal costs, filed a petition with the U.S. Supreme Court to reverse an appeals court verdict that upheld damages to a customer blaming his cancer on the German group's glyphosate-based weedkillers.

  • Christian Lindner-Portfolio: 3 ETFs sind (k)eine gute Anlageidee?
    etf-yogi.de

    Christian Lindner-Portfolio: 3 ETFs sind (k)eine gute Anlageidee?

    Was taugt das Christian Lindner-Portfolio mit 3 ETFs aus dem ARD Sommerinterview. Im aktuellen Artikel habe ich es unter die Lupe genommen.

  • Global Contrast Media Market to Reach $5.2 Billion by 2024
    prnewswire.com

    Global Contrast Media Market to Reach $5.2 Billion by 2024

    /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…

  • The FDA signed off on COVID-19 booster shots for immunocompromised people
    businessinsider.com

    The FDA signed off on COVID-19 booster shots for immunocompromised people

    These are Insider's biggest healthcare stories for the week ending August 13.

  • Recursion Pharmaceuticals : Reports Second Quarter 2021 Financials and Provides Business Updates (Form 8-K)
    marketscreener.com

    Recursion Pharmaceuticals : Reports Second Quarter 2021 Financials and Provides Business Updates (Form 8-K)

    Recursion Reports Second Quarter 2021 Financials and Provides Business Updates

    •Expanded the total number of research and development programs from 37 to… | August 13, 2021

  • Pest Control Market To Touch USD 31.94 Billion at CAGR
    globenewswire.com

    Pest Control Market To Touch USD 31.94 Billion at CAGR

    Pune, India, Aug. 12, 2021 (GLOBE NEWSWIRE) — The global pest control market size is anticipated to witness substantial growth on account of the…

  • India Anti-Fungal Drugs Markets Report 2021: Historical Data 2017-2020, Base Year Of 2021, Estimates For 2022 & Forecasts 2023-2027
    thestreet.com

    India Anti-Fungal Drugs Markets Report 2021: Historical Data 2017-2020, Base Year Of 2021, Estimates For 2022 & Forecasts 2023-2027

    DUBLIN, Aug. 12, 2021 /PRNewswire/ — The “India Anti-Fungal Drugs Market, By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication,

  • Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
    globenewswire.com

    Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

    New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in…

  • Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc.
    markets.businessinsider.com

    Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc.

    SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ — The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing …

  • $86M to California couple upheld in Monsanto pesticide case
    foxbusiness.com

  • Fears Nachawati Law Firm: Chorus Grows for Bayer CEO's Resignation as Juries Return Verdicts in Roundup Cancer Cases
    prnewswire.com

    Fears Nachawati Law Firm: Chorus Grows for Bayer CEO's Resignation as Juries Return Verdicts in Roundup Cancer Cases

    /PRNewswire/ — Cancer victims are calling for Bayer AG CEO Werner Baumann to step down for his failed leadership amid multimillion-dollar jury verdicts…

  • Belmora Seeks Supreme Court Review In "FLANAX" Trademark Battle With German Big Pharma, Bayer AG
    thestreet.com

    Belmora Seeks Supreme Court Review In “FLANAX” Trademark Battle With German Big Pharma, Bayer AG

    WASHINGTON, Aug. 10, 2021 /PRNewswire/ — Belmora LLC, a small Virginia-based pharmaceutical company, has petitioned the U.S. Supreme Court to review two

  • Meet biotech's new potential acquirers
    businessinsider.com

  • Frost & Sullivan Institute Launches Enlightened Growth Leadership Awards Recognizing Top Companies
    markets.businessinsider.com

    Frost & Sullivan Institute Launches Enlightened Growth Leadership Awards Recognizing Top Companies

    SANTA CLARA, Calif., Aug. 9, 2021 /CNW/ — Frost & Sullivan Institute Enlightened Growth Leadership Best Practices Recognition honors organization…

  • BAYER AG : UBS reiterates its Buy rating
    marketscreener.com

    BAYER AG : UBS reiterates its Buy rating

    UBS analyst Michael Leuchten maintains his Buy rating on the stock. The target price remains set at EUR 85. | August 9, 2021

  • Drug Delivery Devices Global Markets Report 2021: COVID-19 Impacts, Implications And Growth Factors To 2030
    thestreet.com

    Drug Delivery Devices Global Markets Report 2021: COVID-19 Impacts, Implications And Growth Factors To 2030

    DUBLIN, Aug. 6, 2021 /PRNewswire/ — The “Drug Delivery Devices Global Market Report 2021: COVID-19 Implications and Growth to 2030” report has been added to

  • BAYER AG : DZ Bank remains its Buy rating
    marketscreener.com

    BAYER AG : DZ Bank remains its Buy rating

    In a research note, DZ Bank analyst Peter Spengler has maintained his recommendation on the stock with a Buy rating. | August 6, 2021

  • BAYER AG : Deutsche Bank reiterates its Buy rating
    marketscreener.com

    BAYER AG : Deutsche Bank reiterates its Buy rating

    In a research note, Deutsche Bank analyst Falko Friedrichs has maintained his recommendation on the stock with a Buy rating. The target price is still set at EUR 66. | August 6, 2021

  • BAYER AG : Berenberg maintains a Buy rating
    marketscreener.com

    BAYER AG : Berenberg maintains a Buy rating

    In a research note, Berenberg analyst Sebastian Bray has maintained his recommendation on the stock with a Buy rating. The target price is decreased from EUR 74 to EUR 60. | August 6, 2021

  • BAYER AG : Barclays remains Neutral
    marketscreener.com

    BAYER AG : Barclays remains Neutral

    Analyst Emily Field from Barclays research gives the stock a Neutral rating. The target price has been revised downwards and is now set at EUR 50 as compared to EUR 55 previously. | August 6, 2021

  • Bayer Starts Latest Roundup Trial With Leg Up After Three Losses
    bloombergquint.com

    Bayer Starts Latest Roundup Trial With Leg Up After Three Losses

    (Bloomberg) — Bayer AG went to trial Thursday over a California woman’s claims the company’s best-selling Roundup weedkiller caused her cancer in what could be the German conglomerate’s best shot at winning a case after three straight losses averaging almost $50 million in damages for each consumer

  • Germany stocks higher at close of trade; DAX up 0.33% By Investing.com
    investing.com

    Germany stocks higher at close of trade; DAX up 0.33% By Investing.com

    Germany stocks higher at close of trade; DAX up 0.33%

  • Bayer Aktiengesellschaft 2021 Q2 - Results - Earnings Call Presentation (OTCMKTS:BAYZF)
    seekingalpha.com

    Bayer Aktiengesellschaft 2021 Q2 – Results – Earnings Call Presentation (OTCMKTS:BAYZF)

    The following slide deck was published by Bayer Aktiengesellschaft in conjunction with their 2021 Q2 earnings call.

  • Global Cancer Therapies Market to Reach $204.2 Billion by 2024
    prnewswire.com

    Global Cancer Therapies Market to Reach $204.2 Billion by 2024

    /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…

  • Futures Rise Ahead Of Claims Data; Europe Hits Another Record High
    zerohedge.com

    Futures Rise Ahead Of Claims Data; Europe Hits Another Record High

    ZeroHedge – On a long enough timeline, the survival rate for everyone drops to zero

  • BAYER AG : Barclays reiterates its Neutral rating
    marketscreener.com

    BAYER AG : Barclays reiterates its Neutral rating

    Barclays's research confirms his advice and maintains his neutral opinion on the stock. The target price is unchanged and still at EUR 55. | August 5, 2021

  • BAYER AG : Buy rating from Bernstein
    marketscreener.com

    BAYER AG : Buy rating from Bernstein

    Bernstein is positive on the stock with a Buy rating. The target price remains set at EUR 75. | August 5, 2021

  • BAYER AG : JP Morgan remains its Buy rating
    marketscreener.com

    BAYER AG : JP Morgan remains its Buy rating

    Richard Vosser from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price is still set at EUR 67. | August 5, 2021

  • Bayer AG reports Q2 results (OTCMKTS:BAYZF)
    seekingalpha.com

    Bayer AG reports Q2 results (OTCMKTS:BAYZF)

    Bayer AG (BAYZF): Q2 Non-GAAP EPS of €1.59; GAAP EPS of -€9.79.Revenue of €10.85B (+8.0% Y/Y) FY21 Guidance: The company now expect to generate sales of approximately €43…

  • Bayer 2Q Net Loss Narrowed Despite Litigation Provisions; Raises 2021 Outlook -- Update
    marketscreener.com

    Bayer 2Q Net Loss Narrowed Despite Litigation Provisions; Raises 2021 Outlook — Update

    By Cecilia Butini

    Bayer AG said Thursday that its net loss for the second quarter narrowed on year despite provisions for Roundup weedkiller litigation, and raised its outlook for the full… | August 5, 2021

  • Bayer to buy US start-up Vividion for up to $2bn
    ft.com

    Bayer to buy US start-up Vividion for up to $2bn

    German drugs group to snap up biopharmaceuticals group in innovation push

  • Bayer boosts drug pipeline with Vividion buy, lifts outlook By Reuters
    investing.com

    Bayer boosts drug pipeline with Vividion buy, lifts outlook By Reuters

    Bayer boosts drug pipeline with Vividion buy, lifts outlook

  • Bayer Raises 2021 View
    marketwatch.com

    Bayer Raises 2021 View

    By Cecilia Butini Bayer AG said Thursday that its net loss for the second quarter narrowed on year, though it set aside provisions for Roundup weedkiller…

  • Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion
    oann.com

    Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion

    Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.

  • Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion By Reuters
    investing.com

    Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion By Reuters

    Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion

  • Biotech vs. Pharmaceuticals: What's the Difference?
    investopedia.com

    Biotech vs. Pharmaceuticals: What's the Difference?

    Biotech and pharma are important industry sectors that differ fundamentally in how they derive medical or healthcare treatments.

  • Insights on the Targeted Therapeutics Global Market to 2031 - Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
    prnewswire.com

    Insights on the Targeted Therapeutics Global Market to 2031 – Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others

    /PRNewswire/ — The “Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031” report has been added to…

  • Insights on the Targeted Therapeutics Global Market to 2031 - Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
    markets.businessinsider.com

    Insights on the Targeted Therapeutics Global Market to 2031 – Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others

    DUBLIN, July 30, 2021 /PRNewswire/ — The 'Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 202…

  • The Worldwide Contraceptives Industry is Expected to Reach $29.6 Billion by 2028
    prnewswire.com

    The Worldwide Contraceptives Industry is Expected to Reach $29.6 Billion by 2028

    /PRNewswire/ — The “Contraceptives Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product, End User, Distribution Channel” report has been…

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der Bayer Aktie

Das Unternehmen Bayer aus Deutschland beschäftigt 100.029 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharmazeutika, Spezialchemie, LifeScience, Kunststoffe, Medizinische Produkte / Medizintechnik, Chemie, Biotechnologie, Pharma tätig.

Tochterunternehmen von Bayer sind: Bayer Cropscience Ltd/India, Bayer CropScience Limited.

Bayer ist in mehr als 82 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter First Trust Indxx Global Agriculture ETF gewichtet Bayer mit 9,59% im ETF.

Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Bayer Anleihen auf einen Blick.

Entdecke die 6 ETFs in denen Bayer am höchsten gewichtet ist Insgesamt in 82 ETFs enthalten

Dir gefallen die Informationen zu Bayer?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Bayer?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Bayer?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba

Dir gefallen die Informationen zu Bayer?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero